Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Virginia Commonwealth University to Study Genomics-based Diagnostic Test

By Drug Discovery Trends Editor | November 6, 2007

Pathwork Diagnostics, a genomics-based diagnostics company focused on oncology, announced that Virginia Commonwealth University School of Medicine has initiated an investigational study of the Pathwork Tissue of Origin Test. The new genomics-based test is designed to help determine a tumor’s origin so that tissue-specific management can begin. VCU’s study makes it one of the first institutions in the country to evaluate this leading technology in patients who may have few remaining diagnostic options. The Tissue of Origin Test is also the focus of two workshops and two poster presentations at the 12th Annual Meeting of the Association for Molecular Pathology.

“Patient cases in which a tumor cannot be readily identified are a significant problem,” said Catherine Dumur, Ph.D., Director of Molecular Morphology Genomics for the Department of Pathology, VCU. “Such cases are time-consuming for physicians and anxiety-producing for patients, and are a challenge to providing the most appropriate care for the patient. We are eager to see how this investigational new genomics-based test extends and complements traditional histopathological approaches.”

There are an estimated 200,000 cancer patients each year in the United States who may benefit from additional diagnostic information to determine the tissue of origin for their cancer. National Comprehensive Cancer Network guidelines emphasize the importance of identifying the tissue of origin so that management specific to the primary cancer can begin.

“We envision that in the future genomics data will become a useful ancillary tool to pathologists to answer complex cancer questions in a clinical setting,” said Carleton Garrett, M.D. Ph.D., Director of the Tissue and Data Acquisition and Analysis Core at VCU. “Virginia Commonwealth University will continue to evaluate the use of such innovative technologies in order to ensure that our cancer patients continue to receive the best possible care.”

The Pathwork Tissue of Origin Test’s proprietary analytics are designed to measure the expression of more than 1600 genes and compare a tumor’s genetic “signature” against those of 15 known tissue types. The test uses microarray technology, which enables large numbers of genes to be evaluated at the same time, using the proven, commercially available Affymetrix instrument system. Up until now, microarrays have been used primarily as research tools but presented challenges for use in clinical settings.

“Our unique processes have enabled us to overcome the challenges of applying microarray technology for clinical use and develop clinically useful diagnostic tests using microarray-based data,” explained Pathwork President and C.E.O. Deborah J. Neff. “The microarray is a great platform because we can look at so many pieces of information simultaneously.” 

Note: The Pathwork Tissue of Origin Test is not cleared by the FDA for sale in the U.S. It is for Investigational Use Only.

Source: Pathwork Diagnostics
Release date: November 6, 2007

 


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Scanning electron micrograph of a cluster of Acinetobacter baumannii bacteria.
New antibiotics need AI that gets resistance right
New cell imaging method reveals hidden enzyme activity 
Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE